Akash Tewari

New Capabilities

Covers Merck; cut remigromig's peak sales estimate after the BRUNELLO data

Jefferies cut its risk-adjusted peak sales estimate for remigromig by 60%, to $300 million. The change followed Merck's presentation of full one-year BRUNELLO results at the American Academy of Ophthalmology meeting in October. In the 984-patient trial, the drug matched ranibizumab on vision but produced smaller gains and higher rates of proliferative diabetic retinopathy.

Updated Oct 26